OXT and major depressive disorder: For example, single-dose intranasal administration of oxytocin reduced amygdala reactivity and functional connectivity to fear-inducing stimuli in individuals with generalized social anxiety disorders (50, 51), and repeated doses of intranasal oxytocin over four weeks added to pharmacological treatment with escitalopram improved depressive symptoms in individuals with treatment-resistant major depressive disorders (52).